Daiichi Sankyo Company Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Daiichi Sankyo Company ha aumentado sus beneficios a una tasa media anual de 31.4%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 12.6% anual. Los ingresos han ido creciendo a una tasa media de 17.3% al año. La rentabilidad financiera de Daiichi Sankyo Company es de 15.4%, y sus márgenes netos son de 11.8%.

Información clave

31.44%

Tasa de crecimiento de los beneficios

32.18%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	5.95%
Tasa de crecimiento de los ingresos	17.31%
Rentabilidad financiera	15.44%
Margen neto	11.82%
Última actualización de beneficios	30 Jun 2026

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Daiichi Sankyo Company. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

OTCPK:DSNK.Y Ingresos, gastos y beneficios (JPY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 26	2,223,188	262,865	821,339	475,510
31 Mar 26	2,123,045	279,728	751,725	466,005
31 Dec 25	2,052,148	304,599	805,873	473,098
30 Sep 25	1,978,882	279,895	763,275	460,310
30 Jun 25	1,924,678	295,873	736,433	441,201
31 Mar 25	1,886,256	295,756	731,200	435,965
31 Dec 24	1,795,986	245,770	722,045	410,753
30 Sep 24	1,758,071	250,400	696,740	392,404
30 Jun 24	1,687,028	229,101	675,532	388,731
31 Mar 24	1,601,688	200,731	636,997	365,169
31 Dec 23	1,503,471	186,052	578,348	358,217
30 Sep 23	1,397,025	147,885	538,976	357,008
30 Jun 23	1,348,996	147,350	511,428	343,791
31 Mar 23	1,278,478	109,188	471,221	341,570
31 Dec 22	1,182,201	59,354	435,551	331,522
30 Sep 22	1,122,724	62,816	404,552	301,836
30 Jun 22	1,061,140	50,603	375,565	281,129
31 Mar 22	1,044,892	66,972	358,309	260,228
31 Dec 21	1,034,692	94,470	357,377	232,834
30 Sep 21	1,012,313	86,756	348,080	231,885
30 Jun 21	989,638	79,321	340,406	232,560
31 Mar 21	962,516	75,958	333,079	227,353
31 Dec 20	963,552	70,599	323,363	224,168
30 Sep 20	982,388	116,315	320,481	216,129
30 Jun 20	969,501	117,584	310,949	205,104
31 Mar 20	981,793	129,074	302,320	197,465
31 Dec 19	983,669	148,891	287,414	198,066
30 Sep 19	962,440	113,821	279,588	195,904
30 Jun 19	953,219	112,805	275,245	199,435
31 Mar 19	929,717	93,409	277,695	203,711
31 Dec 18	922,228	66,479	283,615	203,000
30 Sep 18	937,648	70,018	290,411	206,117
30 Jun 18	946,829	55,081	296,677	233,531
31 Mar 18	960,195	60,282	301,845	236,046
31 Dec 17	961,766	37,887	298,758	246,479
30 Sep 17	966,509	38,758	300,781	242,153
30 Jun 17	953,255	52,017	303,760	215,721
31 Mar 17	955,124	53,466	302,475	214,347
31 Dec 16	962,296	59,736	316,918	214,027
30 Sep 16	965,681	60,572	325,970	216,074
30 Jun 16	989,001	77,951	326,613	211,564
31 Mar 16	986,446	82,282	328,755	208,656
31 Dec 15	839,759	55,256	269,399	186,615
30 Sep 15	872,744	67,132	284,021	190,206

Ingresos de calidad: DSNK.Y tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio(11.8%) de DSNK.Y son inferiores a los del año pasado (15.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lDSNK.Y han crecido significativamente en un 31.4% al año.

Acelerando crecimiento: DSNK.Y ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: DSNK.Y tuvo un crecimiento negativo de los beneficios (-11.2%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (1%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera de DSNK.Y (15.4%) se considera baja.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/09 12:12
Precio de las acciones al final del día	2026/09/09 00:00
Beneficios	2026/06/30
Ingresos anuales	2026/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Daiichi Sankyo Company, Limited está cubierta por 28 analistas. 15 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Daiichi Sankyo Company Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Daiichi Sankyo Company, Limited to Report Q1, 2027 Results on Jul 31, 2026

Daiichi Sankyo Company, Limited to Report Q4, 2026 Results on Apr 27, 2026

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Recent updates

Daiichi Sankyo And AstraZeneca Receive Approval For Enhertu Plus Pertuzumab As First-Line Treatment For HER2 Positive Metastatic Breast Cancer In The EU

Daiichi Sankyo Presents New Data On Bempedoic Acid In Real-World Management Of Dyslipidemia And Cardiovascular Risk

Daiichi Sankyo and Astrazeneca Initiate Tropion-Urothelial04 Phase 3 Trial of Datroway as Adjuvant Therapy in High-Risk Muscle Invasive Urothelial Cancer

Daiichi Sankyo Co., Ltd. Announces Executive Changes

AstraZeneca PLC And Daiichi Sankyo Co., Ltd. Report Enhertu Demonstrates Statistically Significant Improvement In Progression-Free Survival In First-Line HER2-Mutant Advanced Non-Small Cell Lung Cancer In DESTINY-Lung04 Phase III Trial

Datroway® Approved in the Eu as Only Trop2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic Tnbc Who Are Not Candidates for Immunotherapy

Datroway Recommended for Approval in EU for TNBC

Daiichi Sankyo and AstraZeneca Receive Approval for Enhertu as First Tumor Agnostic HER2 Directed Therapy in the EU

Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Daiichi Sankyo Company, Limited to Report Q1, 2027 Results on Jul 31, 2026

Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Suntory Holdings Limited signed a letter of intent to acquire Daiichi Sankyo Healthcare Co., Ltd. from Daiichi Sankyo Company, Limited (TSE:4568) for approximately ¥250 billion.

Daiichi Sankyo Company, Limited to Report Q4, 2026 Results on Apr 27, 2026

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Datroway Approves in Us for EGFRm Lung Cancer

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 17,000,000 shares, representing 0.91% for ¥50,000 million.

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited Provides Updated on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Daiichi Sankyo's Datopotamab Deruxtecan is Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd)